Quest, Ciphergen deal will build intellectual capital
This article was originally published in Clinica
Executive Summary
US firms Ciphergen Biosystems and Quest Diagnostics have formed a strategic alliance to develop and commercialise assay tests based on Ciphergen's proprietary SELDI ProteinChip technology. Under the terms of the agreement, Quest has also claimed a 17.4% stake in Ciphergen, with an option to extend.